Neuraminidase of influenza A and B viruses plays a critical role in the virus life cycle and is
an important target of the host immune system. Here, we highlight the current understanding …

Antibodies have been used to prevent or treat viral infections since the nineteenth century,
but the full potential to use passive immunization for infectious diseases has yet to be …

Messenger RNA (mRNA) vaccines represent a new, effective vaccine platform with high
capacity for rapid development. Generation of a universal influenza virus vaccine with the …

Rapidly evolving influenza A viruses (IAVs) and influenza B viruses (IBVs) are major causes
of recurrent lower respiratory tract infections. Current influenza vaccines elicit antibodies …

Neuraminidase (NA) is one of the two influenza virus surface glycoproteins, and antibodies
that target it are an independent correlate of protection. However, our current understanding …

There is growing appreciation for neuraminidase (NA) as an influenza vaccine target;
however, its antigenicity remains poorly characterized. In this study, we isolated three …

Current seasonal influenza virus vaccines do not induce robust immune responses to
neuraminidase. Several factors, including immunodominance of hemagglutinin over …

Improved vaccines and antiviral agents that provide better, broader protection against
seasonal and emerging influenza viruses are needed. The viral surface glycoprotein …

The diversified classification and continuous alteration of influenza viruses underscore for
antivirals and vaccines that can counter a broad range of influenza subtypes. Hemagglutinin …

Improved broad-spectrum influenza virus vaccines are desperately needed to provide
protection against both drifted seasonal and emerging pandemic influenza A viruses (IAVs) …